These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39042847)

  • 1. Public Views on Whether the Use of Pharmaceutical Neuroenhancements Should Be Allowed.
    Hendriks S; Li X; Grady C; Kim SY
    Neurology; 2024 Aug; 103(4):e209681. PubMed ID: 39042847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should germline genome editing be allowed? The effect of treatment characteristics on public acceptability.
    van Dijke I; van Wely M; Berkman BE; Bredenoord AL; Henneman L; Vliegenthart R; Repping S; Hendriks S
    Hum Reprod; 2021 Jan; 36(2):465-478. PubMed ID: 33242333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroenhancement in French and Romanian University Students, Motivations and Associated Factors.
    Brumboiu I; Porrovecchio A; Peze T; Hurdiel R; Cazacu I; Mogosan C; Ladner J; Tavolacci MP
    Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33917251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.
    Muir D; Orlando C; Newton B
    Campbell Syst Rev; 2024 Jun; 20(2):e1406. PubMed ID: 38873396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.
    Boot BP; Partridge B; Hall W
    Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "It Was Me on a Good Day": Exploring the Smart Drug Use Phenomenon in England.
    Vargo EJ; Petróczi A
    Front Psychol; 2016; 7():779. PubMed ID: 27303339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroenhancement: State of the Art and Future Perspectives.
    Marazziti D; Avella MT; Ivaldi T; Palermo S; Massa L; Vecchia AD; Basile L; Mucci F
    Clin Neuropsychiatry; 2021 Jun; 18(3):137-169. PubMed ID: 34909030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.
    Graf WD; Nagel SK; Epstein LG; Miller G; Nass R; Larriviere D
    Neurology; 2013 Mar; 80(13):1251-60. PubMed ID: 23486879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The is and ought of the Ethics of Neuroenhancement: Mind the Gap.
    Forlini C; Hall W
    Front Psychol; 2015; 6():1998. PubMed ID: 26779100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of the use of prescription stimulants as "study drugs" by UK university students: A brief report.
    Jones F; Newton PM
    Brain Behav; 2024 Feb; 14(2):e3419. PubMed ID: 38346719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How perceived substance characteristics affect ethical judgement towards cognitive enhancement.
    Mayor E; Daehne M; Bianchi R
    PLoS One; 2019; 14(3):e0213619. PubMed ID: 30870469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
    Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
    Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The implications of methylphenidate use by healthy medical students and doctors in South Africa.
    Beyer C; Staunton C; Moodley K
    BMC Med Ethics; 2014 Mar; 15():20. PubMed ID: 24592964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol.
    Perrenoud B; Velonaki VS; Bodenmann P; Ramelet AS
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):82-94. PubMed ID: 26571285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. True and false concerns about neuroenhancement: a response to 'Neuroenhancers, addiction and research ethics', by D M Shaw.
    Heinz A; Kipke R; Müller S; Wiesing U
    J Med Ethics; 2014 Apr; 40(4):286-7. PubMed ID: 23468510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On pharmacological neuroenhancement as part of the new neurorights' pioneering legislation in Chile: a perspective.
    Cornejo-Plaza MI; Saracini C
    Front Psychol; 2023; 14():1177720. PubMed ID: 37533709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee.
    Larriviere D; Williams MA; Rizzo M; Bonnie RJ;
    Neurology; 2009 Oct; 73(17):1406-12. PubMed ID: 19776378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive neuroenhancement: false assumptions in the ethical debate.
    Heinz A; Kipke R; Heimann H; Wiesing U
    J Med Ethics; 2012 Jun; 38(6):372-5. PubMed ID: 22228818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.